Three separate peer-reviewed studies have now identified that ibogaine can cause dangerous heart rhythm problems (QT prolongation and ventricular arrhythmia). When FDA (the US drug regulator) sees this kind of signal in published research, it typically issues a formal Drug Safety Communication warning doctors and the public. However, because ibogaine is currently Schedule I (completely illegal under federal law with no approved medical use), the FDA might decide it doesn't have to issue a formal warning — it's already illegal anyway. This matters because a formal warning carries legal weight and could influence state-level decisions about whether to allow ibogaine access.
Three simultaneous peer-reviewed cardiac risk papers constitute the signal density FDA pharmacovigilance typically requires to act. Congressional veterans-access pressure creates urgency to issue guidance preemptively. However, FDA Safety Communications typically follow adverse event clusters in approved or widely-used drugs; ibogaine remains Schedule I with no approved indication, which may lower FDA's procedural obligation to issue a formal DSC versus informal guidance or a public statement. Confidence trimmed to reflect this procedural uncertainty.